Slides
Page 1
IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) Imricor's vision is to bring iCMR to every cardiac centre in the world FEBRUARY 25TH 2026 FY 2025 Investor Presentation WWW.IMRICOR.COM For personal use only
Page 2
The material contained in this document is a presentation of general background information on Imricor Medical Systems, Inc. (Imricor) and its activities current as of the date of this presentation. It should be read in conjunction with Imricor’s periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at www.asx.com.au. The information is supplied in summary form and is therefore not necessarily complete. It is not intended that it be relied upon as advice to investors or potential investors, who should consider seeking independent professional advice depending upon their specific investment objectives, financial situation or particular needs. The material contained in this presentation may include information derived from publicly available sources that have not been independently verified. None of Imricor, its officers, directors, employees and agents, nor any other person makes any representation or warranty as to the accuracy, completeness or reliability of the information contained in this presentation and none of them accepts responsibility or liability for any errors or omissions in this presentation whatsoever. Unless otherwise noted, financial information in this presentation has been prepared in accordance with accounting principles generally accepted in the U.S. (US GAAP) and are denominated in US dollars. This presentation may contain statements that constitute “forward-looking statements”. Forward- looking statements are statements about matters that are not historical facts. Forward-looking statements appear in a number of places in this presentation and include statements regarding Imiricor’s intent, belief or current expectations with respect to its business and operations, market conditions, results of operations and financial condition. Imricor uses words such as ‘will’, ‘may’, ‘expect’, ‘intend’, ‘seek’, ‘would’, ‘should’, ‘could’, ‘continue’, ‘plan’, ‘estimate’, ‘anticipate’, ‘believe’, ‘probability’, ‘risk’, ‘aim’, or other similar words to identify forward-looking statements. These forward-looking statements reflect Imricor’s current views with respect to future events and are subject to change, certain risks, uncertainties and assumptions which are, in many instances, beyond its control, and have been made based upon management’s expectations and beliefs concerning future developments and their potential effect upon Imricor. There can be no assurance that future developments will be in accordance with Imricor’s expectations or that the effect of future developments on Imricor will be those anticipated. Actual results could differ materially from those which we expect, depending on the outcome of various factors. Investors and others are cautioned not to place undue reliance on forward-looking statements. Imricor is under no obligation to update any forward-looking statements contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation. Imricor’s CHESS Depositary Interests (CDIs) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation. The distribution of this document outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in the United States or in any other jurisdiction. Disclaimer WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 For personal use only
Page 3
Delivering key milestones in 2025 Financial • CE Mark approval under MDR for 2nd generation ablation catheter and capital equipment • CE mark approval received for NorthStar – world’s only MRI native 3D mapping and guidance system • Successfully performed first-in-human ischemic VT ablation under real time MRI guidance • Successfully completed human factors study involving circa 20 U.S. hospitals to support FDA approval • Added Charité in Berlin to VISABL-VT study • Submitted NorthStar and Vision-MR Diagnostic Catheter for 510(k) clearance by FDA • Added UVA Health as 2nd U.S. hospital to join VISABL-AFL clinical trial • World first in vivo PFA ablations performed in the ventricle under real time MRI guidance • Completed integration and testing of NorthStar on Philips MRI platform unlocking Philips sites • Completed hiring and training of European sales team • European customer pipeline grew from 7 in Q4 24 to 40 in Q4 25 • Construction of iCMR labs commenced in Saudi Arabia with completion expected Q2 CY26 • 100 doctors attended the iCMR summit in Saudi Arabia hosted by Imricor and KOL from Amsterdam • Revenue of US$292k temporarily impacted by customer sites performing clinical trial cases • Strengthened balance sheet to support growth via a cUS$44m institutional placement • Costs well managed with operating cash outflow of US$19m in FY25 • US$40.8m cash and marketable securities as at Dec 31 st 2025 Commercial Regulatory & Clinical WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 For personal use only
Page 4
Imricor is moving cardiac ablations From X-Ray Cath Labs To MRI Cath Labs WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 • Boston Scientific • Johnson&Johnson MedTech • Abbott • Medtronic • AtriCure • Kardium 100% of consumable revenue captured For personal use only
Page 5
Imricor’s solution – adding value to all stakeholders WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Patient • Higher single procedure success rates achieved in clinical trials for AFL patients • Single procedure success is expected to result in lower overall treatment costs per patient • Faster average procedure times in clinical trials for AFL patients • No radiation exposure • Improved visualisation of heart anatomy and lesion verification • Faster procedures can allow for more cases per day • No radiation exposure • No lead garments to wear and therefore avoid potential occupational injuries • Similar or lower per-procedure costs • Lower overall cost per patient expected to result from higher single procedure success rate • Existing reimbursement applies • Similar cost to set up an iCMR EP lab compared to X-ray EP lab • iCMR EP lab can be used for diagnostic imaging when not being used for interventions • Shorter procedure times = higher volume • Radiation eliminated for patients, physicians, and staff • Similar or lower cost per procedure; improved patient treatment Doctor Payer Hospital For personal use only
Page 6
Regulatory process is gaining momentum WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Geography Regulation Imricor Product Suite Pathway Status Details Europe • NorthStar • Advantage-MR EP Recorder/Stimulator • Vision-MR Diagnostic Catheter 2.0 • Vision-MR Diagnostic Cable • Vision-MR Ablation Catheter 2.0 • Vision-MR Ablation Cable Set 2.0 • NavTrac-MR Cable • Vision-MR Dispersive Electrode Full technology platform to perform real-time iCMR guided atrial flutter procedures now approved for commercialization across Europe. United States • NorthStar • Vision-MR Diagnostic Catheter • Vision-MR Diagnostic Cable • Vision-MR Dispersive Electrode • Advantage-MR EP Recorder/Stimulator • NavTrac-MR Steerable Introducer and Dilator • NavTrac-MR Cable • NavTrac-MR Steerable Introducer and Dilator (x-ray use) • Vision-MR Ablation Catheter 2.0 • Vision-MR Ablation Cable Set 2.0 • RF5000 Ablation Generator, Pump, and Remote Multiple 510(k) reviews are cleared/under review. Multiple 510(k) submissions progressing toward submission. PMA modules 1 and module 2 submitted. PMA module 3 nearing submission. Clinical trial site expansion complete. 510(k) PMA Med Dev Reg For personal use only
Page 7
Board of directors strengthened to support growth and commercialisation WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 “Throughout my 30-year career at companies such as Medtronic and Johnson & Johnson MedTech, I have witnessed remarkable innovations that have reshaped the landscape of healthcare and improved millions of lives. Yet it is rare toencounter a technology with the potential to redefine an entire field as profoundly as Imricor’s MRI-guided platform. What Imricor has developed is not an incremental improvement. It represents a paradigm shift in the way electrophysiology and other interventional procedures are performed. ” Aldo Denti Non-executive Director - Imricor For personal use only
Page 8
Financial WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Performance For personal use only
Page 9
Profit and loss WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 US$’000 FY25 FY24 Revenue 292 959 Costs and non-R&D expenses (11,418) (8,643) R&D expenses (10,866) (7,865) Other income (expenses), net 624 306 EBITDA (21,368) (15,243) Depreciation & Amortization (799) (748) EBIT (22,167) (15,991) Finance income (costs), net 1,176 238 Foreign exchange gain 1,510 198 Fair value change (5,838) (14,138) Net loss before tax (25,319) (29,693) Income tax benefit - - Net loss after tax (25,319) (29,693) Underlying net loss after tax (20,991) (15,753) Equipment Revenue $38 Consumable $171 Service & Other Revenue $83 FY25 Revenue US$’000 • Revenue decrease on prior comparative period (pcp) is the result of customer sites enrolling trial patients, a 3rd party capital sale in Europe and a consumable sale to new distributor in pcp. • Costs and non-R&D expenses increased primarily due to staffing costs ($2,177). • R&D expenses increased due to higher staffing ($2,496) and costs for clinical trials and regulatory approvals ($485). • Net loss impacted by change in fair value of convertible note, which does not have a direct impact on future cashflow • Underlying net loss of $20.99 million up 33% on pcp Commentary For personal use only
Page 10
Balance sheet WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 US$’000 Dec-25 Dec-24 Cash and cash equivalents 19,502 15,708 Marketable securities 21,278 - Accounts receivable 241 345 Inventory 1,096 1,502 Other current assets 800 794 Total current assets 42,917 18,349 PP&E, net 1,538 1,879 Inventory, long term 415 328 Operating lease right of use assets 604 718 Other long-term assets 282 350 Total long-term assets 2,839 3,275 Total assets 45,756 21,624 Accounts payable 496 335 Accrued expenses 1,620 1,493 Current portion of convertible notes 11,746 - Current portion of option liabilities 3,158 - Other current liabilities 351 528 Total current liabilities 17,371 2,356 Convertible note 13,269 19,870 Option and warrant liabilities, net of current 1,829 4,667 Long-term contract liabilities 1,086 1,098 Other long-term liabilities 678 1,010 Total long-term liabilities 16,862 26,645 Total liabilities 34,233 29,001 Share capital 179,121 134,903 Accumulated losses (167,598) (142,280) Total equity 11,523 (7,377) • Cash, cash equivalents, and marketable securities balances total $40.8 million • Convertible note held at fair value under US GAAP; outstanding principal and interest at 31 December was $6.6 million • Option and warrant liabilities relate to securities issued as part of previous financing activities and are held at fair value under US GAAP Commentary For personal use only
Page 11
US$’000 FY25 FY24 Net loss (25,319) (29,693) Other non-cash adjustments 6,339 14,889 Change in other assets and liabilities (101) (770) Operating cash flows (19,081) (15,574) Purchases of property and equipment (434) (75) Purchases of marketable securities, net (21,278) - Investing cash flows (21,712) (75) Proceeds from issuance of common stock (net) 43,256 31,009 Other financing activities (210) (666) Financing cash flows 43,046 30,334 Net change in cash 2,253 14,685 Effect of foreign currency changes on cash 1,541 191 Cash at 30 June 19,502 15,708 Marketable securities 21,278 - Total cash and marketable securities 40,780 15,708 Cash flow WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 • Other non-cash adjustments were down vs. pcp primarily due to decreases in the change in fair value charges. • Purchases of marketable securities were $21.3m • Proceeds from issuance of common stock: • 2025 proceeds reflect the Company’s March placement • 2024 proceeds reflect the Company’s placements launched in February and July Commentary For personal use only
Page 12
WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Looking ahead to 2026 & beyond For personal use only
Page 13
A strong and growing market in cardiac ablation WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Drivers of global catheter ablation market Increased incidence of cardiac disease Shift towards minimally invasive procedures Cost effectiveness of catheter ablation as treatment option 0 5 10 15 20 25 30 35 40 2023 2024 2025 2026 2027 2028 2029 2030 2032 Electrophysiology Devices Market Size US$bn United States ROW 15% CAGR A large global addressable market with high growth potential supported by favourable growth drivers Sources: S&S Insider Strategy and Stats For personal use only
Page 14
Pipeline benefiting from investment in sales WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 0 5 10 15 20 25 30 35 40 45 Q4 -24 Q2-25 Q4-25 European active pipeline is rebuilding Imricor’s products are currently approved in 31 countries, with 8 countries containing customer sites Estimated over 1,500,000 ablation procedures across the US, EU and Aus in 2026, with growth in these markets estimated at 15% CAGR to 2032 Average estimated consumable revenue of USD $3,500 - $6,500 per procedure depending on indication and market Expected US, ANZ, Nordics, and additional Middle East countries will be activated within the next 6-12 months For personal use only
Page 15
VISABL-AFL Clinical Trial Sites – Atrial Flutter sets the stage WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 DR. AV KOLANDAIVELU Johns Hopkins University “MRI is the gold standard for imaging arrhythmia causing heart characteristics, like fibrosis, and for visualizing the effects of ablation. We are enthusiastic to be a part of the FDA approval study for the Imricor ablation system.” DR. LAURENT FIORINA Cardiovascular Institute of South Paris “Performing procedures with Imricor's NorthStar 3D Mapping System is a game changer for this field, and it will have a transformative impact. I look forward to the continued partnership with Imricor.” “Interventional CMR, particularly for electrophysiology applications, promises to advance our therapeutic strategies for patients with atrial and ventricular arrhythmias by facilitating visualization of the catheters used for ablation simultaneously with real- time CMR imaging.” DR. KENNETH BILCHICK University of Virginia Health DR. EDWARD MARTIN Oklahoma Heart Institute “I have been involved with the imaging aspect of cardiac MRI for the last 30 years, and I have seen and participated in many exciting technological advances over that time. I am extremely excited to see the advancements... that allow expansion of cardiac MRI into interventional electrophysiology.” PROF . JUERG SCHWITTER MD, Director Cardiac MR Centre, University Hospital Lausanne (CHUV) “Many years ago in San Francisco, we did pioneering work on coronary artery disease detection by MRI. Now ischemia diagnostics by MRI is in all international guidelines. Similarly, pacemakers and defibrillators were not compatible with MRI 10 years ago. We started a collaboration with industry, and now all leading device manufactures offer a full spectrum of devices, all MRI compatible, reaching market shares up to 100%. I believe strongly, that this evolution will also happen to the iCMR field, as it allows for high precision interventions, where we expect higher success rate, lower relapse rate and less complications compared to conventional techniques, and all these advantages go without radiation exposure and potentially shorter interventions times.” DR. AJAY PILLAI Virginia Commonwealth University Health “Imricor’s Northstar mapping system and Vision-MR mapping and ablation catheters represent a paradigm shift in cardiac ablation. The potential to visualize arrhythmogenic substrate and, crucially, the effects of ablation is extraordinarily impactful and meaningful for patient outcomes.” DR. MARCO GÖTTE Amsterdam University Medical Center “With MRI-guided treatment of heart conditions, we are working towards fewer procedures per patient, hospital admissions, and less medication. Perhaps MRI-guided treatment of heart disease will become the norm and replace X-ray-driven treatments.” For personal use only
Page 16
Ventricular Tachycardia changes the game WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Intracardiac echo provides partial visualization of the septum but adds workflow burden and disposable cost per case Most VT and AF ablations target the left side of the heart, so operators must cross the inter-atrial septum safely and precisely With X-ray, soft tissue is largely invisible. Operators infer position from catheters and contrast, increasing complexity and variability VT & AF Limited soft tissue view ≈ $2,000 / case Left-sided access is required X-ray fluoroscopy can’t show the septum nor the heart ICE adds guidance …. and cost For personal use only
Page 17
Ventricular Tachycardia changes the game WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Dedicated mapping catheters add disposable cost, and high-fidelity mapping can take hours in VT cases. Scarring on the heart can form narrow channels within regions of dead and viable tissue — the pathways that sustain VT and must be targeted. With fluoroscopy blind to myocardium, operators build electroanatomical maps point- by-point — often hundreds of samples. Scar channels 3D mapping Catheters + time VT substrate is hard to find Hundreds of points per case Mapping adds cost and hours ≈ $2000 For personal use only
Page 18
The Imricor solution WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Ablation targets identified, ablated and verified, aiming for chronic success in one procedure No need for ICE catheter eliminates procedural cost and workflow step. MRI eliminates the need for mapping catheter, eliminating cost and saving time Full MRI of heart Shell creation & scar identification in NorthStar Targets ablated under real-time MRI imaging MRI used to cross the septum Shells created from the actual heart images Ablation under real-time MRI guidance For personal use only
Page 19
WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 US Top 50 Hospitalsby volume AFL VT Afib Total Average procedures pa 434 173 1010 1617 Imricor estimated ASP US$ per procedure $4000 $6500 $6500 Revenue opportunity per hospital for Imricor $1.7m $1.1m $6.6m $9.43m Device cost savings per hospital pa* $192k $539k $3.89m $4.62m *Savings do not include lab time savings which can exceed $2000 per hour iCMR Lab Economics better outcomes, higher throughput, higher margins For personal use only
Page 20
NorthStar – Cleared and ready for commercialisation WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 NorthStar Mapping System Key piece of the infrastructure, intended to be the central hub of every iCMR lab AI powered application potential well beyond cardiac ablation Strong in-bound interest from hospitals Solves problem for pediatric hospitals where radiation minimisation is a key priority Regulatory status European CE mark received US FDA cleared For personal use only
Page 21
Several key value drivers during 2025/26 WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 FDA Approval for US commercial release of platform technology • 510(k) submissions / approvals • VISABL-AFL clinical trial expands in U.S. • PMA submissions / approvals VISABL-VT clinical trial • Expansion of trial in EU to high volume sites with strong KOL’s NorthStar Mapping System U.S. Market Launch New site activations, growing installed base globally Middle East first procedures and further expansion Pipeline building in United States following NorthStar approval Pulsed Field Ablation (PFA) research, publications, and product development For personal use only
Page 22
Questions? WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 For personal use only
Page 23
WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Appendix For personal use only
Page 24
A strong intellectual property portfolio WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Imricor’s patents protect technology that allows Imricor to manufacture medical devices that are uniquely MRI compatible. Trade secrets, 3rd party relationships and difficult regulatory environment leave a deep moat behind Imricor. In addition to protecting Imricor’s devices and procedures, its patents provide an opportunity for the Company to license its technology to 3rd party medical device companies (particularly implant manufacturers) to help make their devices compatible with MRI. To date, Imricor has executed 3 separate agreements where it has licensed its own patents to 3rd parties for use in implantable devices under which Imricor has received over US$12.9m of payments (revenue) to date. 19 issued U.S patents 71 granted foreign patents 1 U.S. patent allowed 4 pending 2 published For personal use only
Page 25
Imricor Leadership: Management WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 JONATHON GUT Vice President of Finance and Chief Financial Officer 15 years industry experience Previous experience at Gail Medical and Boston Scientific driving financial performance, supporting business growth, and ensuring regulatory compliance. Expertise spans various aspects of financial management, strategic planning, and operational efficiency within the medical device industry. GREGG STENZEL Vice President of Research and Development 25 years industry experience Led the Instrument Technical Operations division at Beckman Coulter, Inc., a leading manufacturer of In Vitro Diagnostic Systems. Seasoned operations executive with expertise in new product development, supply chain management, quality and regulatory systems, and customer support. JENNIFER WEISZ Vice President of Regulatory and Quality 20 years industry experience Contributed to the continuous improvement of the quality and regulatory strategy, development, and implementation during tenure at Medtronic’s Global Clinical Operations Quality division. Experienced in bringing medical devices to market and ensuring their compliance with global standards. 35 years industry experience Designed MRI and ultrasound systems for GE Healthcare. United States appointed expert on MR safety and devices. Credited with establishing the 4 th known hazard interaction in the MRI STEVE WEDAN President and Chief Executive Officer, and Board Chair NICK CORKILL Vice President of Corporate Strategy 16 years industry experience Experienced capital markets professional having spent 15 years as an equity analyst and portfolio manager at Perpetual Investments, BlackRock Inc and Lennox Capital. Deep analytical and financial modelling skills across multiple sectors, disciplined approach to capital management. GREG ENGLEHARDT Vice President of Global Sales 20 years industry experience Led global business development initiatives, identifying and capitalizing on new market opportunities to drive international sales growth at NeuroMetrix. Former combat medic in the U.S. Army VIC FABANO Vice President of Operations 25 years industry experience Held executive positions in Operations, Quality, and Product Development throughout his tenure including VP of Operations and Quality at Osprey Medical. Expert in supply chain scaling and operations infrastructure to support rapid growth, profitability, and quality for start-up to midsize medical device firms NICK TWOHY Vice President of Marketing and Business Development 20 years industry experience Directed international market strategies for Medtronic’s Cardiac Resynchronisation Therapies business Led the successful US launch of the Medtronic Revo MRI pacemaker system, enhancing market. KATE LINDBORG, PHD Vice President of Clinical Affairs 13 years industry experience Managed a portfolio of clinical trials within Medtronic’s Cardiac Rhythm and Heart Failure and Diagnostics Clinical division to gain and maintain market approval of novel devices. Oversaw the generation and dissemination of clinical evidence, enhancing the scientific credibility and market positioning of Medtronic's products. For personal use only
Page 26
Imricor Leadership: Board of directors IMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 STEVE WEDAN President and Chief Executive Officer, and Board Chair Designed MRI and ultrasound systems for GE Healthcare. United States appointed expert on MR safety. Mr Wedan is a member of various international standards committees in the fields of MRI safety and the compatibility of implanted and interventional products in MRI Credited with establishing the 4 th known hazard interaction in the MRI MARK TIBBLES Deputy Chair and Lead Independent Director Entrepreneur, business owner, company director and active venture investor in and advisor to technology, life science and medical device companies Owner and managing member of STEM Fuse, LLC, one of the largest providers of digital K-12 STEM curriculum in the U.S. Managing Director of Strategic Stage Ventures, LLC. PETER MCGREGOR Non-executive Director Extensive finance management background including partner positions at Goldman Sachs JBWere, and managing director in the institutional banking & markets division of Commonwealth Bank of Australia Currently serves as a Director of Treasury Corporation of Victoria and True Infrastructure Management Pty Ltd. ANITA MESSAL Non-executive Director Comprehensive background in health care and benefits industry, including the successful integration of merged and acquired entities across all areas of the business at AccentCare Vast background in working with both Fortune 100 and startup companies in public, private and non-profit sectors in both domestic and international markets JEFFREY LEIGHTON Non-executive Director Dr Leighton is a cognitive neuroscientist with extensive experience in both academic and corporate settings. He holds a PhD in Cognitive Psychology from Grand Canyon University and has a robust research, teaching, and leadership background. Beyond his academic achievements, Dr Leighton has demonstrated strong business acumen as CFO at NDS Wellness. Dr Leighton has held key corporate governance and advisory roles. ALDO DENTI Non-executive Director Mr Denti has over 30 years of global experience in the medical device industry. Mr Denti is currently the Chief Commercial Officer for Dentsply Sirona. Prior to this role, he was the Company Group Chairman of Global Orthopaedics for Johnson & Johnson MedTech. Since becoming Company Group Chairman in 2019, Mr Denti grew the business to US$9 billion in annual sales, making it the world’s largest orthopaedics company. Mr Denti was responsible for leading a staff of over 25,000 employees. Prior to his role in orthopaedics, Mr Denti served as Global Leader at Johnson & Johnson Vision, where he modernized the organization and introduced critical new skill sets in strategic planning, insights & analytics, e-commerce, and business model innovation. Mr Denti holds a Bachelor of Arts, with Specialised Honors, from York University For personal use only
Page 27
Key terms WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Vision-MR Ablation Catheter • Medical device developed by Imricor, designed for use within an MRI • World first, no competitors, all others only compatible with X-ray Cardiac Arrythmias • Irregular heartbeat, affects approximately 2% of US population • Expected to double to 4% of US population by 2030 • Ventricular arrhythmias are responsible for 75% - 85% of sudden cardiac deaths, and are a leading cause of strokes Ablation • Minimally invasive surgical procedure to restore heart to normal heartbeat Catheter Ablation • Physician will guide catheter into heart • Physician will then apply energy (radiofrequency, cryo, pulsed field) with the purpose of forming scars/lesions that destroy the heart cells responsible for causing the electrical misfiring X-ray vs MRI • X-rays are good for bones and bone density, not as effective at visualizing soft tissues like muscles, ligaments, and organs • MRI provides excellent contrast between different types of soft tissues, making it ideal for imaging the heart • CMR is the field of MRI used by cardiologists (“Cardiac MR”) • CMR field has grown over 500% since 1998 iCMR Lab: Interventional Cardiac Magnetic Resonance • A speciality interventional lab fitted with MRI used by cardiologists (interventional + CMR = iCMR) • Earning potential of over US$1 million p.a. more than a standard X-ray lab for each hospital performing 500 procedures per year For personal use only
Page 28
Contact information WWW.IMRICOR.COMIMRICOR MEDICAL SYSTEMS, INC (ASX:IMR) FEBRUARY 25TH 2026 Investors: Steve Wedan Executive Chair, President & CEO Email: steve.wedan@imricor.com Investors & Australian Media: Simon Hinsley NWR Communications simon@nwrcommunications.com.au +61 401 809 653 Rest of World Media: Nick Twohy Vice President, Marketing & Business Development Email: nick.twohy@imricor.com Nick Corkill Vice President, Corporate Strategy Email: nick.corkill@imricor.com FOLLOW US For personal use only